Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Afatinib (Primary) ; Cetuximab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AFACET
- 07 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 12 Nov 2018 New trial record
- 08 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Nov 2018.